Organization | Chong Qing Reproducive and Genetic Institute

Chong Qing Reproducive and Genetic Institute Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial

2015

NCT02655146

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

chong qing reproductive and genetic institute

Active Ingredients

Drugs in Phase 4 Trials (3)

estradiol (progynon depot) (1 trial)

progesterone (progestasert) (1 trial)

triptorelin (Trelstar) (2 trials)

Drugs in Other Trials (3)

follitropin beta (Follistim) (1 trial)

ganirelix (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Infertility (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial APIs: 6